The first participants for two new clinical trials have been recruited in Bradford as part of research into treatments for respiratory conditions.

The research involves UK and Europe based participants and is being run by the National Institute for Health and Care Research (NIHR) Patient Recruitment Centre (PRC) at Bradford Teaching Hospitals NHS Foundation Trust.

The trials will be investigating the effect of innovative, potential treatments for respiratory conditions.

This includes adults with uncontrolled asthma and people with chronic obstructive pulmonary disease (COPD) alongside a history of exacerbations. 

The two randomised, placebo-controlled trials are being led by renowned biopharmaceutical company, AstraZeneca.

The AJAX Phase II study is looking at the safety and efficacy of a potential treatment (known as AZD4604) for adults with uncontrolled asthma.

The second trial, MIRANDA, is a Phase III study of tozorakimab, an investigational treatment focusing on participants with COPD.

It comes as PRC Bradford becomes an official care partner with AstraZeneca.

The strategic collaboration is hoped to open further opportunities for the centre to recruit patients for studies of potential new medicines across a range of disease areas.

Professor Dinesh Saralaya, Director of the PRC Bradford, said: “This collaboration allows people living with respiratory conditions in and around Bradford early access to cutting-edge treatments.”